FindMyKOL
Clinical trialNCT05167500CompletedObservational

Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment

SponsorFundación GECPEnrollment118Metastatic Non Small Cell Lung Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is an observational, non-interventional, retrospective, multicentre and nationwide study. The information will be obtained retrospectively, in most cases when the treatment has already ended. The primary objective of this study is determine the activity of lorlatinib (percentage of responses, duration of response, progression-free survival and time to treatment failure) of patients included in the compassionate use program in Spain.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

25 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Spain
  • Hospital Clínico Santiago

    Santiago de Compostela, A Coruña, Spain

  • Hospital Germans Trias I Pujol

    Badalona, Barcelona, Spain

  • Hospital Puerta del Mar

    Cadiz, Cádiz, Spain

  • Hospital Universitario Insular de Gran Canaria

    Las Palmas de Gran Canaria, Gran Canaria, Spain

  • Centro Oncológico de Galicia

    A Coruña, La Coruña, Spain

  • Complejo Hospitalario Universitario A Coruña

    A Coruña, La Coruña, Spain

  • Hospital Universitario Central de Asturias

    Oviedo, Principality of Asturias, Spain

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Hospital Universitari Quiron Dexeus

    Barcelona, Spain

  • Hospital del Mar

    Barcelona, Spain

  • Hospital Universitario de Burgos

    Burgos, Spain

  • Hospital Dr. Josep Trueta

    Girona, Spain

  • Hospital Universitario de Jaén

    Jaén, Spain

  • Complejo Asistencial Universitario de León

    León, Spain

  • Hospital 12 de Octubre

    Madrid, Spain

  • Hospital Clínico San Carlos

    Madrid, Spain

  • Hospital Fundación de Alcorcón

    Madrid, Spain

  • Hospital Gregorio Marañón

    Madrid, Spain

  • Hospital Puerta de Hierro

    Madrid, Spain

  • Hospital Virgen del Rocio

    Seville, Spain

  • Complejo Hospitalario de Toledo

    Toledo, Spain

  • Hospital Clínico de Valencia

    Valencia, Spain

  • Hospital General de Valencia

    Valencia, Spain

  • Hospital Universitari I Politécnic la Fe

    Valencia, Spain

  • Hospital Clínico Lozano Blesa

    Zaragoza, Spain

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Lorlatinib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
9 Dec 2021
Primary completion
30 Dec 2022
Completion
30 Dec 2022
Last update posted
30 Mar 2023
Registered enrollment
118
Registry id
NCT05167500
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.